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Restrictocin is a ribonucleolytic toxin produced by the fungus
Aspergillus restrictus. Two chimaeric toxins containing
restrictocin directed at the human transferrin receptor have been
constructed. Anti-TFR(scFv)–restrictocin is encoded by a gene
produced by fusing the DNA encoding a single-chain antigen-
combining region (scFv) of a monoclonal antibody, directed at
the human transferrin receptor, at the 5« end of that encoding
restrictocin. The other chimaeric toxin, restrictocin–anti-
TFR(scFv), is encoded by a gene fusion containing the DNA
encoding the single-chain antigen-combining region of antibody
to human transferrin receptor at the 3« end of the DNA encoding
restrictocin. These gene fusions were expressed in Escherichia
coli, and fusion proteins purified from the inclusion bodies by
INTRODUCTION
Restrictocin is a ribosome-inactivating toxin produced by the
fungus Aspergillus restrictus which is grouped in a class of
protein toxins termed ribotoxins [1]. This class includes two
other proteins, a-sarcin and mitogillin, produced by different
strains of Aspergillus [2,3]. These toxins are shown to be extremely
potent inhibitors of translation, and cleave a single phos-
phodiester bond in the 28S rRNA leading to a total collapse
of the protein-synthesis machinery [4]. These toxins catalyse
covalent modification of a single nucleotide out of nearly 7000
nucleotides in a mammalian ribosome, which results in the total
inactivation of the ribosome and is responsible for the toxicity
[5]. Ribosomes of all organisms have been found to be sensitive
to inactivation by ribotoxins [6]. The ribotoxin a-sarcin has been
shown to inhibit protein synthesis in certain tumour cell lines,
albeit when present at very high concentrations [7]. Ribotoxins
do not bind to any cell surface receptor and, when introduced
inside the cell by artificial means, they manifest extremely potent
cytotoxicity [8]. a-Sarcin has been shown to be a powerful
inhibitor of protein synthesis in picornavirus-infected cells and
also in Xenopus oocytes on microinjection [9,10]. Gasset and co-
workers [11,12] have demonstrated interaction of a-sarcin with
phospholipid vesicles in model systems, which could be an
indication of their ability to translocate intracellularly to reach
their target in the cytosol.
Protein toxins from bacterial, plant and fungal sources have
been successfully employed tomake immunotoxins and chimaeric
toxins by chemical means and gene-fusion technology respect-
ively to selectively kill cells bearing specific receptors or antigens
[13–15]. In the preclinical and clinical evaluation these chimaeric
toxins appear to be quite promising for the treatment of a variety
of malignancies [13–19]. In addition to their practical application
as therapeutic agents, chimaeric toxins are also proving to be
useful tools for the study of the mechanisms of toxin action,
Abbreviations used: Anti-TFR(scFv), single-chain Fv region of anti-(transferrin receptor) antibody; DT, diphtheria toxin ; PE, Pseudomonas exotoxin
A; DMEM, Dulbecco’s modified Eagle’s medium; Tos-Lys-CH2Cl, tosyl-lysylchloromethane (‘TLCK’).
* To whom correspondence should be addressed.
simple chromatography techniques to near-homogeneity. The
two chimaeric toxins were found to be equally active in inhibiting
protein synthesis in a cell-free in itro translation assay
system. The chimaeric toxins were selectively toxic to the target
cells in culture with potent cytotoxic activities. However,
restrictocin–anti-TFR(scFv) was more active than anti-
TFR(scFv)–restrictocin on all cell lines studied. By using protease
and metabolic inhibitors, it can be shown that, to manifest their
cytotoxic activity, the restrictocin-containing chimaeric toxins
need to be proteolytically processed intracellularly and the free
toxin or a fragment thereof thus generated is translocated to the
target via a route involving the Golgi apparatus.
intracellular translocation and sorting of proteins [20–23]. The
mechanism of cell intoxication by protein toxins involves cell
binding, intracellular translocation and target modification. Since
ribotoxins do not have any intrinsic cell binding activity and
have potent toxic activity along with a probable intrinsic
translocating activity, they appear to be potential candidates for
development as chimaeric toxins.
Earlier ribotoxins have been used in the construction of
immunotoxins by chemical means [24–28]. We have found
recombinant restrictocin to have poor immunogenic activity, a
desirable property for components of immunotoxins}chimaeric
toxins, and therefore we made active immunotoxins targeted at
the human transferrin receptor [28]. Although chimaeric
molecules have been made using the bacterial toxins Pseudomonas
exotoxin A (PE) and diphtheria toxin (DT), fungal
ribonucleolytic toxins, although being equally potent in itro,
have not so far been used. Here we report on the construction
and characterization of restrictocin-based chimaeric toxins.
Single-chain antigen-combining region (scFv) of an anti-(human
transferrin receptor) antibody [anti-TFR(scFv)] was used as a
model ligand and genetically fused separately at the N- and C-
termini of restrictocin. The proteins were expressed in Escherichia
coli and purified to homogeneity. The chimaeric toxins were
tested on a variety of human cancer cell lines for their cytotoxic
activity. Also, their intracellular mode of action was investigated
with respect to proteolytic processing and translocation.
EXPERIMENTAL
Materials
Restriction and modifying enzymes were purchased from
Gibco–BRL or Boehringer. [$H]Leucine and "#&I were obtained
from Amersham. Reagents for in itro translation assay were
from Promega and Pharmacia. All cell culture reagents were
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from Gibco–BRL. All cancer cell lines and 5E9C11, a hybridoma
producing the anti-(transferrin receptor) monoclonal antibody
HB21, were obtained from the ATCC.
Construction of plasmids
pAnti-TFR(scFv)–restrictocin
pAnti-TFR(scFv)–restrictocin contains DNA coding for anti-
TFR(scFv) at the 5« end of restrictocin DNA under the control
of a phage T7 promoter. Plasmid pJB anti-TFR(Fv)-1108 [29],
containing anti-TFR(scFv) insert, was used as template to
amplify the anti-TFR(scFv) fragment by PCR such that it
contained recognition sites for XbaI and NdeI at the 5« and 3«
ends respectively. The 760 bp fragment obtained was digested
with XbaI and NdeI and ligated into pRest, which contains
restrictocin in a T7-promoter-based bacterial expression vector,
which was also digested with the same enzymes. E. coli strain
DH5a was used for DNA manipulation. The correct clones were
identified by restriction analysis and protein expression.
pRestrictocin–anti-TFR(scFv)
pRestrictocin–anti-TFR(scFv) contains DNA coding for anti-
TFR(scFv) at the 3« end of restrictocin DNA under the control
of a phage T7 promoter. Restrictocin DNA was amplified by
PCR using pRest as template, and NdeI recognition sites were
created at both the 5« and 3« ends of the fragment. DNA coding
for anti-TFR(scFv) was amplified by PCR using pJB anti-
TFR(Fv)-1108 as template such that the fragment contained
NdeI and EcoRI sites respectively at the 5« and 3« ends. A three-
fragment ligation was set up with restrictocin fragment digested
with NdeI, scFv fragment digested with NdeI and EcoRI and the
expression vector, pVex11, digested with NdeI and EcoRI. The
correct clones were identified by restriction analysis and protein
expression.
Expression and purification of chimaeric toxins
E. coli strain BL21 (kDE3) was used for expression. Cells were
separately transformed with pAnti-TFR(scFv)–restrictocin or
pRestrictocin–anti-TFR(scFv) and grown in super broth at 37 °C
containing 100 lg}ml ampicillin. The cultures were induced at an
A
'!!
of 2±0, with 1 mM isopropyl b-d-thiogalactopyranoside,
for 2 h. Inclusion bodies were isolated from the total cell pellet
and processed using the protocol described [30]. Briefly, inclusion
bodies were denatured in guanidinium chloride and reduced by
dithioerythritol, followed by renaturation in refolding buffer
containing arginine and oxidized glutathione. Renatured material
after dialysis was loaded on an S-Sepharose column (Pharmacia),
equilibrated with 50 mM sodium phosphate buffer, pH 6±3.
Fusion protein was eluted with a linear gradient from 0 to
1 M NaCl in 50 mM sodium phosphate, pH 6±3, using an FPLC
system (Pharmacia), and purified to homogeneity by gel-filtration
chromatography on a TSK 3000 column (LKB).
Ribonucleolytic activity of chimaeric toxins
The ribonucleolytic activity of fusion proteins and recombinant
restrictocin was assayed by measuring the inhibition of protein
synthesis in the presence of toxins in a rabbit-reticulocyte-lysate-
based in itro translation assay system. Rabbit reticulocyte lysate
was prepared and the assay performed as described [31]. Serial
dilutions of chimaeric toxins were tested over the range 0±5–500
ng}ml. Incorporation of [$H]leucine was measured as a function
of toxin concentration. ID
&!
was calculated by comparing with
uninhibited protein samples.
Cytotoxicity and specificity of chimaeric toxins
The activity of fusion proteins was tested on a variety of human
cancer cell lines. Protein synthesis in these cells was assayed in
the absence and presence of various concentrations of toxins by
measuring [$H]leucine incorporation. Adherent cells were plated
at a density of 5¬10$}well in 96-well plates, 16 h before the
addition of toxin. Cells growing in suspension were seeded at a
density of 5¬10$}well in 96-well plates in 80% leucine-free
Dulbecco’s modified Eagle’s medium (DMEM) containing 18%
RPMI 1640 and 2% serum, and used immediately. All dilutions
of the toxin were made in PBS containing 0±2% human serum
albumin. After 48 h, adherent cells were washed twice with
leucine-free DMEM and labelled for 2 h with 0±25 lCi of
[$H]leucine. Suspensed cells were directly labelled with 0±5 lCi
of [$H]leucine for 2 h. The cells were harvested and counted on
filtermats using an LKBb-plate counter. The results are expressed
as percentage of control, to which no toxin was added. For
competition experiments, 10 lg of anti-(transferrin receptor)
antibody (HB21) was added per well before the addition of the
fusion protein.
Kinetics of protein-synthesis inhibition
The time course of inhibition of protein synthesis was investigated
by incubating K562 cells at a density of 2¬10%}well in a 96-well
plate with different concentrations of chimaeric toxin at 37 °C
for various time periods. At the end of each incubation period,
protein synthesis was measured. Results are expressed as de-
scribed above.
Binding studies
Anti-(transferrin receptor) antibody (HB21) was iodinated by
the lactoperoxidase method [32]. "#&I-labelled antibody was added
as tracer at a concentration of 1±5 ng per assay. HUT102 and
A431 cells, at a density of 4¬10&}well, were used for the assay.
Cells were washed twice with binding buffer (DMEM containing
0±1% BSA), before the addition of various concentrations of
fusion proteins in 0±2 ml of binding buffer. Cells were incubated
with shaking for 2 h at room temperature. At the end of the
incubation, cells were washed three times with binding buffer,
and counted directly in a c-counter (LKB).
Effect of metabolic inhibitors on the cytotoxicity of chimaeric
toxins
K562, A431 and HUT102 cells were used to study the effect of
NH
%
Cl and brefeldin A. Cells were incubated for 2 h with
5 mM NH
%
Cl and then for a further 36 hours after the addition of
fusion protein. The effect of brefeldin A was evaluated by adding
it at a concentration of 0±05 lg}ml, 18 h after the addition of
toxin. Cells were incubated for a further 18 h and then [$H]leucine
was added as described above.
Effect of protease inhibitors on the cytotoxicity of chimaeric toxin
A549 cells were used to study the effect of pepstatin A, leupeptin
and tosyl-lysylchloromethane (Tos-Lys-CH
#
Cl) on the cyto-
toxicity of chimaeric toxins. Cells were incubated for 48 h with
chimaeric toxins in the presence of pepstatin A (0±15 mM),
leupeptin (0±40 mM) or Tos-Lys-CH
#
Cl (0±27 mM). Cytotoxicity
was measured as described.
RESULTS
We have previously shown that immunotoxins constructed
with anti-(transferrin receptor) monoclonal antibody and
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Figure 1 Schematic representation of chimaeric toxins
In anti-TFR(scFv)–restrictocin, anti-TFR(scFv) was fused at the N-terminus of restrictocin, whereas in the case of restrictocin–anti-TFR(scFv) it was fused at the C-terminus of restrictocin. The scFv
region contains the first 110 amino acids of the heavy and light chains of the anti-(transferrin receptor) antibody held together by a 15-amino-acid peptide linker composed of (Gly4Ser)3.
Figure 2 Purification of chimaeric toxins
(A) and (B) represent anti-TFR(scFv)–restrictocin and restrictocin–anti-TFR(scFv) respectively.
An SDS/12% polyacrylamide gel was run and stained with Coomassie Blue. Lane 1, total cell
pellet ; lane 2, inclusion bodies ; lane 3, protein after S-Sepharose column ; lane 4, protein after
gel filtration. The molecular masses of the markers (in kDa) are shown on the left.
recombinant restrictocin possess considerable cytotoxicity in
itro against a wide variety of target cells [28]. In the present
study we constructed chimaeric toxins in which cDNA encoding
anti-TFR(scFv) was fused to that for restrictocin. We produced
two molecules that differed in the site of attachment of the ligand
with respect to the toxin. Human transferrin receptor has been
frequently used as a model target for investigating the efficacy of
immunotoxins, since it is identified as a marker of rapid cell
proliferation and is expressed at higher densities on tumour cells
than on most normal cells [17,28,29,33,34]. Transferrin receptor
has been successfully used for targeting ricin-A-chain- and DT-
based immunotoxins to treat central nervous system malignancies
[17].
Construction of chimaeric toxins
DNA encoding anti-TFR(scFv) was cloned separately at the 5«
and 3« ends of restrictocin DNA in a T7-promoter-based bacterial
expression vector to respectively generate gene fusions coding for
anti-TFR(scFv)–restrictocin (referred to from here on as
Fv–restrictocin) and restrictocin–anti-TFR(scFv) (referred to
from here on as restrictocin–Fv). The structures of these
constructs are illustrated in Figure 1. The scFv region consists of
variable heavy and light chains of the anti-(human transferrin
receptor) antibody held together by a 15-amino-acid linker
containing (Gly
%
Ser)
$
and has been shown to contain full antigen-
binding activity of the antibody [29]. In the construction of a
chimaeric toxin, the site of attachment of the ligand on the toxin
can be critical. As chimaeric toxins were being made for the first
time with restrictocin, we constructed Fv–restrictocin and
restrictocin–Fv, containing the Fv portion of the antibody
Figure 3 Effect of chimaeric toxins on translation in cell-free assay system
Rabbit reticulocyte lysate was incubated with different concentrations of anti-
TFR(scFv)–restrictocin (E), restrictocin–anti-TFR(scFv) (+) and restrictocin (D) for 1 h at
30 °C, and proteins were precipitated with 20% trichloroacetic acid. Precipitated material was
collected on a glass-fibre filter and counted on a b-counter for [3H]leucine incorporation.
respectively at the N- and C-termini of restrictocin (Figure 1). In
both cases, protein of the expected molecular mass (44 kDa) was
overexpressed in E. coli, where it accumulated in spheroplasts in
the form of insoluble inclusion bodies (Figure 2). Inclusion
bodies were purified from the total cell pellet, and solubilized in
guanidinium chloride. The reduced and denatured proteins were
refolded in an arginine-rich buffer containing oxidized
glutathione. After renaturation, proteins were purified by suc-
cessive chromatography on cation-exchange and gel-filtration
columns (Figure 2). Both proteins were more than 90% pure
after the gel-filtration step. The yield of restrictocin–Fv was
considerably higher than that of the Fv–restrictocin, typical
yields being 6–8 mg}l and 1–2 mg}l respectively.
In vitro activity of chimaeric toxins
Protein-synthesis-inhibitory activity of the chimaeric toxins con-
taining restrictocin was evaluated in a cell-free translation assay
system containing rabbit reticulocyte lysate to investigate whether
extending the N- or C-terminus of restrictocin by fusing proteins
alters the activity of the toxin. As shown in Figure 3,
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Figure 4 Effect of chimaeric toxins on various cell lines
Anti-TFR(scFv)–restrictocin (D, E) or restrictocin–anti-TFR(scFv) (*, +) was added to the cells in the absence (D, *) or presence (E, +) of excess (50 lg/ml) anti-(transferrin receptor)
antibody for 48 h at 37 °C. [3H]Leucine incorporation was measured as described.
Fv–restrictocin and restrictocin–Fv inhibited translation of en-
dogenous globin mRNA in a dose-dependent manner with an
ID
&!
of 2±2 nM. Chimaeric toxins were about 30-fold less active
than recombinant restrictocin, which had an ID
&!
of 70 pM in
the same assay (Figure 3).
Cytotoxicity and specificity of chimaeric toxins
Activity of both the fusion toxins was tested on a variety of
human cell lines by a quantitative assay in which their ability to
inhibit protein synthesis was measured on target and non-target
cell lines. The fusion proteins inhibited protein synthesis in target
cells in a dose-dependent manner (Figure 4). Both restrictocin–Fv
and Fv–restrictocin showed maximum activity on K562 cells,
which express transferrin receptor in excess, with ID
&!
values of
0±05 and 0±56 nM respectively. The chimaeric toxins exhibited
similar activities on HUT102 cells, which have fewer transferrin
receptors than K562 cells, with ID
&!
values of 0±1 and 0±4 nM for
restrictocin–Fv and Fv–restrictocin respectively (Table 1, Figure
4). Invariably, restrictocin–Fv was found to be more active than
Fv–restrictocin, the cytotoxicity being 3–12-fold higher
depending on the cell line (Table 1). The cytotoxic activity of
chimaeric toxins was specific, as addition of an excess of anti-
(transferrin receptor) antibody prevented the cytotoxic effect of
the chimaeric toxins (Figure 4). In addition, both proteins had no
cytotoxic activity on a murine cell line L929, and no inhibition of
protein synthesis was observed even at a concentration of
115 nM, indicating the specific binding of the proteins to the
human transferrin receptor (Table 1). Restrictocin alone also did
not show any activity up to 115 nM (results not shown).
Binding of chimaeric toxins to the transferrin receptor
The cytotoxicity of restrictocin–Fv, depending on the cell line,
was 3–12-fold higher than that of Fv–restrictocin. In no case
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Table 1 Cytotoxic activity of fusion proteins on various cell lines
Human cancer cell lines K562 (erythroleukaemia), HUT102 (T-cell leukaemia), MCF7 (breast
adenocarcinoma), COLO205 (colon adenocarcinoma), A431 (epidermoid carcinoma), A549 (lung
carcinoma), HeLa (cervical carcinoma) and L929 (a mouse fibroblast cell line) were used to test
the cytotoxic activity of the chimaeric toxins. All assays were carried out at least three times,
and variations in the ID50 values were within 10%. Relative cytotoxicity is the ratio of activity
of restrictocin–anti-TFR(scFv) to anti-TFR(scFv)–restrictocin on the same cell line.
ID50 (nM)
Relative
Cell line Restrictocin–Anti-TFR(scFv) Anti-TFR(scFv)–Restrictocin cytotoxicity
K562 0±05 0±56 11±2
HUT102 0±10 0±40 4±0
A549 0±22 0±68 3±1
COLO205 0±45 1±30 2±9
MCF7 0±63 2±50 4±0
HeLa 0±90 11±30 12±5
A431 1±50 6±80 4±5
L929 " 115±00 " 115±00
were the cytotoxicities of the two proteins similar or
Fv–restrictocin more active than restrictocin–Fv. As the in itro
ribonucleolytic activity of the two proteins is similar, the
differences in the cytotoxic activities could be due to differences
in (i) their affinities for the transferrin receptor or (ii) their
intracellular translocation or processing. To check whether the
differential cytotoxic activity was due to a difference in the
binding of the two proteins to transferrin receptor, competition
binding analyses were performed on HUT102 and A431 cells by
measuring the ability of the two chimaeric toxins to compete for
the binding of "#&I-anti-(transferrin receptor) antibody. The two
proteins were found to be equally potent in binding to the
transferrin receptor (Figure 5). Also, their binding activities were
found to be similar to that of the native antibody, indicating that
the folding of the ligand was correct (Figure 5). Since the fusion
proteins bind the cell surface receptor equally well and have
similar activities in the in itro translation assay system, the
differences in their cytotoxic activity appear to be due to
intracellular factors or events.
Figure 5 Binding activity of chimaeric toxins
Iodinated anti-(transferrin receptor) antibody was added as tracer with increasing amounts of anti-TFR(scFv)–restrictocin (E), restrictocin–anti-TFR(scFv) (+) or native anti-(transferrin receptor)
antibody (D) on HUT102 and A431 cells. Cells were incubated at room temperature for 2 h ; bound label was then assessed using a c-counter.
Table 2 Kinetics of intoxication of chimaeric toxins
K562 cells at a density of 2¬104/0±2 ml of medium were incubated with the fusion toxins for
various lengths of time. [3H]Leucine incorporation was measured as described.
ID50 (ng/ml)
Time (h) Restrictocin–anti-TFR(scFv) Anti-TFR(scFv)–restrictocin
12 " 1000 " 1000
24 300 1000
36 20 60
48 10 35
60 20 42
72 30 50
Kinetics of protein-synthesis inhibition
To determine the minimum amount of time required to induce
maximum inhibition of protein synthesis, K562 cells were
incubated with the fusion proteins for various time intervals
ranging from 12 to 72 h at 37 °C. Protein synthesis was measured
as described. After an initial lag of 12 h, Fv–restrictocin and
restrictocin–Fv started to show protein-synthesis-inhibitory ac-
tivity, and by 24 h had respective ID
&!
values of 1000 and 300
ng}ml. Activities reached a peak by 48 h when the ID
&!
values
were 35 and 10 ng}ml respectively (Table 2). The values remained
relatively stable for the rest of the experiment (Table 2). In-
toxication kinetics of restrictocin-based chimaeric toxins are
slow compared with those of PE- and DT-containing toxins,
where peak cytotoxicity is observed in less than 24 h [29].
The slow kinetics of intoxication for the restrictocin-based
immunotoxins further indicates involvement of an intracellular
rate-limiting step subsequent to the internalization of the
immunotoxins.
Effect of metabolic inhibitors on the toxicity of fusion protein
On internalization, the endocytosed protein toxins need to be
translocated intracellularly to meet the cytosolic target, which
may involve different pathways for different toxins [20,35,36]. To
trace the intracellular translocation pathway followed by
restrictocin-based chimaeric toxins, the effect of NH
%
Cl and
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Table 3 Effect of metabolic inhibitors on the cytotoxicity of chimaeric
toxins
K562 cells at a density of 2¬104/0±2 ml of medium were incubated with chimaeric toxins in
the absence or presence of the indicated inhibitors. [3H]Leucine incorporation was measured
as described.
ID50 (ng/ml)
Inhibitors Restrictocin–anti-TFR(scFv) Anti-TFR(scFv)–restrictocin
None 8 62
NH4Cl 10 90
Brefeldin A 200 1200
brefeldin A (which affect the normal functioning of different
subcellular organelles) was checked on the cytotoxicity of
Fv–restrictocin and restrictocin–Fv. NH
%
Cl diffuses readily into
the cells in the uncharged form, and, in intracellular acidic
compartments, tends to become protonated and unable to diffuse
out, leading to an increase in the pH of the endosomal com-
partment [37]. Brefeldin A causes dissolution of cis-, medial and
trans-Golgi lamellae and blocks the transport of proteins into
post-Golgi organelles [38]. NH
%
Cl did not affect the activities of
Fv–restrictocin and restrictocin–Fv in any of the cell lines tested;
results for K562 cells are shown in Table 3. In the same
experiment, NH
%
Cl protected the cells from the toxicity of
DT–anti-TFR(Fv), a chimaeric toxin containing DT fused to the
anti-TFR(scFv) (results not shown). An acidic endosomal pH is
required for DT activity, and an increase in pH therefore
protected the cells from DT toxicity. NH
%
Cl alone inhibited
protein synthesis by 25–30%. The results have been corrected
for this inhibition. Brefeldin A protected the cells from
restrictocin–Fv and Fv–restrictocin toxicity, their cytotoxicities
decreasing by about 20-fold on K562 cells in the presence of
brefeldin A (Table 3). A similar result was obtained for HUT102
and A431 cells (results not shown). A long exposure of cells to
brefeldin A was found to be lethal, therefore experiments were
carried out using low concentrations of brefeldin A and exposing
the cells for only 18 h.
Effect of protease inhibitors on the cytotoxicity of fusion proteins
Chimaeric toxins, subsequent to internalization, may require
proteolytic processing to generate an active fragment of the toxin
capable of interacting with the intracellular target [39–41]. To
investigate the probable involvement of an intracellular pro-
Table 4 Effect of protease inhibitors on the cytotoxicity of chimaeric toxins
A549 cells seeded at a density of 5¬103/well in 96-well plates 16 h before the experiment
were incubated with the fusion proteins in the absence or presence of various protease inhibitors
for 48 h. [3H]Leucine incorporation was measured as described.
ID50 (ng/ml)
Protease inhibitor Restrictocin–anti-TFR(scFv) Anti-TFR(scFv)–restrictocin
None 4±5 30±0
Pepstatin 6±0 30±0
Leupeptin 6±0 28±0
Tos-Lys-CH2Cl 115±0 1000±0
teolytic processing step, the effect of the protease inhibitors
pepstatin A, leupeptin and Tos-Lys-CH
#
Cl on the cytotoxicity of
restrictocin-based chimaeric toxins was investigated. The aspartic
protease inhibitor, pepstatin A, strongly inhibits acid proteases
such as pepsin [42], whereas leupeptin and Tos-Lys-CH
#
Cl
prevent the activity of serine and thiol proteases such as trypsin,
plasmin, kallikrein, papain and ficin [43,44]. Pepstatin A has
previously been shown to inhibit intracellular proteolysis of the
ricin A chain [45], and leupeptin has been shown to inhibit
intracellular proteolytic processing of DT [41], resulting in
reduction in the respective cytotoxicities of these toxins. In the
present study, under similar conditions, pepstatinAand leupeptin
did not affect the cytotoxic activities of either restrictocin–Fv or
Fv–restrictocin (Table 4). Tos-Lys-CH
#
Cl, however, protected
the cells from the cytotoxicity of both restrictocin–Fv and
Fv–restrictocin, the ID
&!
values increasing 26- and 33-fold
respectively (Table 4). This indicates that proteolytic processing,
perhaps carried out by serine or cysteine protease, is involved in
the cytotoxicity of chimaeric toxins containing restrictocin.
DISCUSSION
Recombinant chimaeric toxins are rationally designed fusion
proteins in which novel cell-binding specificities are generated by
fusing appropriate ligands to toxins such that they are specifically
toxic to the target cell types. A variety of toxins have been used
to construct chimaeric toxins, but the approach cannot be used
universally with every potential toxin to generate a new chimaeric
toxin. Ribotoxins, which lack cell-binding activity and contain
potent toxic activity with low immunogenicity, are excellent
candidates for chimaeric toxin development. In this study we
designed and developed active chimaeric toxins using the
ribotoxin restrictocin, and studied their probable intracellular
mode of action. It has previously been established that the site of
attachment of a ligand to a toxin is crucial. For instance, in the
case of PE, a ligand can only be attached at the N-terminus, and
a free C-terminus is essential for the cytotoxic activity of the
molecule, whereas, in contrast, the ligand must be fused to the C-
terminus in the case of DT-based chimaeric molecules [46,47].
Thus we have made two chimaeric toxins which have the ligand,
anti-TFR(scFv), separately fused at the N- or C-terminus of
restrictocin. We have previously shown that the addition of a few
amino acids at the N-terminus of restrictocin does not affect its
ribonucleolytic activity [48], but the addition of a bulky ligand at
either end of restrictocin resulted in an appreciable loss of
its ribonucleolytic activity in the present study. The decreased
ribonucleolytic activity observed could be due to a change in the
folding pattern of restrictocin, and}or steric hindrance of the
active site by the bulky ligand. The cytotoxic activities of fusion
proteins did not correlate fully with cell surface antigen density.
Both proteins were found to be much more active on K562 than
A431 cells, even though the two cell types express similar numbers
of transferrin receptors. This indicates that, in addition to
receptor-mediated endocytosis, intracellular factor(s) also con-
tribute to the cytotoxicity of restrictocin-based chimaeric toxins.
This is in agreement with the results obtained previously with
chemical conjugates containing restrictocin targeted at the human
transferrin receptor using the monoclonal anti-(transferrin re-
ceptor) antibody HB21 [28].
After binding to its receptor, a chimaeric toxin is internalized
by receptor-mediated endocytosis, followed by proteolytic
processing in some cases ; subsequently the active fragment of the
toxin is translocated to the cytosol [35,36,39–41]. In PE and DT
fusion proteins the translocation-competent toxin fragment is
generated by a specific proteolytic processing step that occurs
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within the target cell [39–41]. It has been shown, using protease
inhibitors, that the cytotoxicity of the ricin A chain is dependent
on the action of specific proteases, and endosomal proteolysis
precedes ricin A chain toxicity in macrophages [45,49]. However,
in chimaeric toxins containing ricin A chain, processing is
inefficient, and introduction of a proteolytically cleavable spacer
sequence dramatically improves the cytotoxicity of these
chimaeric toxins [50]. A proteolytic processing step also appears
to be involved in the cytotoxic action of restrictocin-based
chimaeric toxins. The protease responsible for this processing
does not appear to be an acid protease, since pepstatin A did not
inhibit the cytotoxic activities of the chimaeric toxins. Although
both leupeptin and Tos-Lys-CH
#
Cl are strong inhibitors of
serine proteases, the cytotoxicity of restrictocin-based chimaeric
toxins was prevented only by the latter. This variation in
susceptibility to the inhibitors is not surprising, since enzymes
using similar catalytic mechanisms could be members of different
evolutionary families and thus structurally quite dissimilar [51].
However, the two restrictocin-based chimaeric toxins, which
differ in the position of the Fv portion on the toxin, do not differ
in their in itro ribonucleolytic activity, receptor-binding activity
and intracellular routing, and yet restrictocin–Fv was found to
be more cytotoxic than Fv–restrictocin. The precise reason for
the differential activity remains to be discovered, but it appears
that intracellular proteolytic processing of restrictocin–Fv and
Fv–restrictocin might result in restrictocin fragments that differ
in translocation efficiency and}or interaction with the target
RNA. The activity of both restrictocin–Fv and Fv–restrictocin
remained unaffected in the presence of NH
%
Cl, indicating that an
acidic endosomal environment is not a prerequisite for
processing}translocation of the fusion protein, which is in further
agreement with the observation that inhibition of acid proteases
by pepstatin A did not affect the cytotoxicities of these proteins.
Brefeldin A was able to protect cells from the toxicity of both
restrictocin–Fv and Fv–restrictocin, indicating that the toxin is
translocated intracellularly via a route involving the Golgi
apparatus. Brefeldin A has been shown to prevent intoxication
by ricin, abrin and modeccin [36,52,53]. A similar effect is seen
with PE-based chimaeric toxins [54]. Brefeldin A does not affect
DT intoxication, as processing and translocation of the active
moiety take place in the endosomal compartment [36]. It is
probable that the Golgi is the site of proteolytic processing of
restrictocin–based chimaeric toxins. In comparison with other
protein toxins, intracellular processing}translocation of the
fusion proteins containing restrictocin is apparently less efficient,
which could be the reason for the slow kinetics of intoxication.
Targeted therapy employing chimaeric toxins and im-
munotoxins has great promise, and a number of molecules are
at different stages of preclinical and clinical evaluation [15–19].
There are some associated limitations that are now recognized,
and attempts are being made to resolve them [15–19]. Two major
problems are immunogenicity and dose-limiting toxicity
[13,15,17,19]. It has also been realized that smaller chimaeric
toxins will have better tumour penetration than the bulky
conventional immunotoxins [13]. A small toxin with poor
immunogenicity and low non-specific toxic activity would thus
be ideal for constructing immunotoxins. Furthermore, once an
anti-toxin response begins, a chimaeric toxin directed at the same
target but containing a different toxin could be employed to
circumvent the neutralization. In this context there is a need to
explore novel toxins with desirable properties that could be used
as components of chimaeric toxins, and the present study is a
step in that direction.
In conclusion, we have shown that it is possible to develop
active restrictocin-based chimaeric toxins by placing the binding
ligand at the C-terminus of the toxin. After internalization the
chimaeric toxins appear to be proteolytically processed, and
translocated to the intracellular target via the Golgi apparatus.
The first generation of chimaeric toxins developed with the
ribotoxin restrictocin are quite potent even though they do not
contain the full ribonucleolytic activity of the toxin and it should
now be possible to improve the activity of these chimaeric toxins
by further engineering.
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